EZH2 is involved in cancer initiation and progression mainly due to its transcriptional repression activity in the PRC2 complex, and gain-of-function (GOF) mutants of EZH2 (Y647F/N, A677G, and A687V) are frequently generated in several lymphomas, further promoting tumorigenesis (Figure 5A) [19,20,189]. Here, EZH2 is linked to lymphoma.